Clinical Trial Update: Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older [Phase 2]

View source ↗

Summary

Phase 2 trial of a quadrivalent meningococcal conjugate vaccine in adults 56 and older has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Meningococcal Disease
• Meningitis

Drugs mentioned

• Quadrivalent meningococcal conjugate vaccine (meningococcal conjugate vaccine quadrivalent (MenACWY))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Meningitis | Phase 2 | Status: COMPLETED | Results posted: 2020-06-09